← Back
Tonix Pharmaceuticals Holding
TNXP · listed on Nasdaq · worth $167.05 million
$5.10
−3.41% on Oct 30
Five insider buys in the last year, $172.3K in all. None in the last two weeks.
Green dot = an insider bought◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
14.1M shares
82% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, four insiders bought Tonix Pharmaceuticals Holding stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
Chief Executive Officer
Seth Lederman
Bought $58.9K on Jun 9 — 5,000 shares at $11.79, 56% of what they now own.
No earlier purchases to measure
Director
Richard Newcomb Stillwell
Bought $58.3K on Jun 8 — 5,000 shares at $11.65, 100% of what they now own.
First purchase we have on file
Director
Carolyn E. Taylor
Bought $14.9K on Jun 12 — 1,415 shares at $10.55, 77% of what they now own.
0 of 1 earlier purchase did better than the S&P 500
Big investors
People and funds that reported owning 5% or more of Tonix Pharmaceuticals Holding, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company.Aqr Capital Management LLC5.5%Aug 13
Filed by someone who owns 5% or more and does not plan to influence the company.Millennium Management LLC5.6%Jun 15
Filed by someone who owns 5% or more and does not plan to influence the company. · updatePoint72 Asset Management6.9%May 15Reported stake, oldest first: 9.2% (Dec 31, 2025) → 6.9% (May 15)
Filed by someone who owns 5% or more and does not plan to influence the company.Sirenia Capital Management LP8.8%May 15
Filed by someone who owns 5% or more and does not plan to influence the company. · updateVanguard Group0.0%Mar 27Reported stake, oldest first: 6.3% (Oct 31, 2025) → 5.0% (Jan 30) → 0.0% (Mar 27)
Each history starts at the oldest report we hold.
All reports
Every insider trade and SEC report we hold for Tonix Pharmaceuticals Holding.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Aug 31BoughtSeth LedermanAug 31 · Traded Aug 27 · Chief Executive Officer+18%via a trust or family2,000 @ $13.79$27.6K
2 more with Pro →Analysts, earnings and news
Analysts' price target
$42.40 average
5 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
1 of 5 quarters above
Q2 '26−$2.47 a share+$0.15
Q1 '26−$2.93 a share−$0.39
Q4 '25−$3.98 a share−$1.04
Q3 '25−$3.59 a share−$0.00